Richard Boyce

Learn More
The entire drug safety enterprise has a need to search, retrieve, evaluate, and synthesize scientific evidence more efficiently. This discovery and synthesis process would be greatly accelerated through access to a common framework that brings all relevant information sources together within a standardized structure. This presents an opportunity to(More)
Out-of-date or incomplete drug product labeling information may increase the risk of otherwise preventable adverse drug events. In recognition of these concerns, the United States Federal Drug Administration (FDA) requires drug product labels to include specific information. Unfortunately, several studies have found that drug product labeling fails to keep(More)
BACKGROUND Every year, hundreds of thousands of patients experience treatment failure or adverse drug reactions (ADRs), many of which could be prevented by pharmacogenomic testing. However, the primary knowledge needed for clinical pharmacogenomics is currently dispersed over disparate data structures and captured in unstructured or semi-structured(More)
Inadequate representation of evidence and knowledge about potential drug-drug interactions is a major factor underlying disagreements among sources of drug information that are used by clinicians. In this paper we describe the initial steps toward developing a foundational domain representation that allows tracing the evidence underlying potential drug-drug(More)
BACKGROUND Wikipedia is an important source of medical information for both patients and medical professionals. Given its wide reach, improving the quality, completeness, and accessibility of medical information on Wikipedia could have a positive impact on global health. OBJECTIVE We created a prototypical implementation of an automated system for keeping(More)
BACKGROUND The development of genotyping and genetic sequencing techniques and their evolution towards low costs and quick turnaround have encouraged a wide range of applications. One of the most promising applications is pharmacogenomics, where genetic profiles are used to predict the most suitable drugs and drug dosages for the individual patient. This(More)
Structured Product Labels (SPLs) contain information about drugs that can be valuable to clinical and translational research, especially if it can be linked to other sources that provide data about drug targets, chemical properties, interactions, and biological pathways. Unfortunately, SPLs currently provide coarsely-structured drug information and lack the(More)
Drug-drug interactions (DDIs) are defined as clinically meaningful alterations in the exposure and response to a drug (called object drug) that has occurred as a result of the co-administration of another drug (called precipitant drug). According a 2011 study, drug-drug interactions (DDIs) are responsible for roughly 220,000 hospital admissions per year(More)
BACKGROUND The Web provides widespread access to vast quantities of health-related information that can improve quality-of-life through better understanding of personal symptoms, medical conditions, and available treatments. Unfortunately, identifying a credible and personally relevant subset of information can be a time-consuming and challenging task for(More)
Multiple studies indicate that drug-drug interactions are a significant source of preventable adverse drug events. Factors contributing to the occurrence of preventable ADEs resulting from DDIs include a lack of knowledge of the patient's concurrent medications and inaccurate or inadequate knowledge of interactions by health care providers. FDA-approved(More)